Acute administration of L-dopa induces changes in methylation metabolites, reduced protein phosphatase 2A methylation, and hyperphosphorylation of Tau protein in mouse brain

Journal of Neuroscience

Volumn 32, Issue 27, 2012, Pages 9173-9181

  Bottiglieri, Teodoro ^a   Arning, Erland ^a   Wasek, Brandi ^a   Nunbhakdi Craig, Viyada ^b   Sontag, Jean Marie ^c   Sontag, Estelle ^c  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 O METHYLDOPAMINE; BENSERAZIDE; CATECHOL METHYLTRANSFERASE; DOPAMINE; LEVODOPA; METHYLDOPA; PHOSPHOPROTEIN PHOSPHATASE 2A; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE; TAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DENSITOMETRY; DOWN REGULATION; FOLIC ACID DEFICIENCY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANIMALS; ANTIPARKINSON AGENTS; BRAIN; CELL LINE, TUMOR; DOPAMINERGIC NEURONS; HUMANS; LEVODOPA; MALE; METHYLATION; MICE; MICE, INBRED C57BL; NERVE DEGENERATION; NEUROBLASTOMA; PHOSPHORYLATION; PRIMARY CELL CULTURE; PROTEIN PHOSPHATASE 2; TAU PROTEINS;

EID: 84863431577     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0125-12.2012     Document Type: Article

References (55)

1. Badiola N, de Oliveira RM, Herrera F, Guardia-Laguarta C, Goncalves SA, Pera M, Suárez-Calvet M, Clarimon J, Outeiro TF, Lleó A (2011) Tau enhancessynuclein aggregation and toxicity in cellular models of synucleinopathy. PLoS One 6:e26609.
2. Baldessarini RJ, Karobath M (1972) Effects of L-DOPA and L-3-O-methylDOPA on uptake of (3H)L-methionine by synaptosomes. Neuropharmacology 11:715-720.
3. Belcastro V, Pierguidi L, Castrioto A, Menichetti C, Gorgone G, Ientile R, Pisani F, Rossi A, Calabresi P, Tambasco N (2010) Hyperhomocysteinemia recurrence in levodopa-treated Parkinson's disease patients. Eur J Neurol 17:661-665.
4. Bottiglieri T (1990) Isocratic high performance liquid chromatographic analysis of S-adenosylmethionine and S-adenosylhomocysteine in animal tissues: the effect of exposure to nitrous oxide. Biomed Chromatogr 4:239-241.
5. Bottiglieri T (2005) Homocysteine and folate metabolism in depression. Prog Neuropsychopharmacol Biol Psychiatry 29:1103-1112.
6. Cantoni GL (1987) The role of S-adenosylhomocysteine in the biological utilization of S-adenosylmethionine. Prog Clin Biol Res 198:47-65.
7. Cheng H, Gomes-Trolin C, Aquilonius SM, Steinberg A, Löfberg C, Ekblom J, Oreland L (1997) Levels of L-methionine S-adenosyltransferase activity in erythrocytes and concentrations of S-adenosylmethionine and S-adenosylhomocysteine in whole blood of patients with Parkinson's disease. Exp Neurol 145:580-585.
8. Chiang PK (1998) Biological effects of inhibitors of S-adenosylhomocysteine hydrolase. Pharmacol Ther 77:115-134.
9. Cotzias GC, Papavasiliou PS, Gellene R (1969) Modification of Parkinsonismchronic treatment with L-dopa. N Engl J Med 280:337-345.
10. De Bonis ML, Tessitore A, Pellecchia MT, Longo K, Salvatore A, Russo A, Ingrosso D, Zappia V, Barone P, Galletti P, Tedeschi G (2010) Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa. Neurosci Lett 468:287-291.
11. Ericsson AD (1971) Potentiation of the L-Dopa effect in man by the use of catechol-O-methyltransferase inhibitors. J Neurol Sci 14:193-197.
12. Favre B, Turowski P, Hemmings BA (1997) Differential inhibition and posttranslational modification of protein phosphatase 1 and 2A in MCF7 cells treated with calyculin-A, okadaic acid, and tautomycin. J Biol Chem 272:13856-13863.
13. Fuso A, Scarpa S (2011) One-carbon metabolism and Alzheimer's disease: is it all a methylation matter? Neurobiol Aging 32:1192-1195.
14. Hanger DP, Anderton BH, Noble W (2009) Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 15:112-119.
15. Iqbal K, Liu F, Gong CX, Grundke-Iqbal I (2010) Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 7:656-664.
16. Irizarry MC, Gurol ME, Raju S, Diaz-Arrastia R, Locascio JJ, Tennis M, Hyman BT, Growdon JH, Greenberg SM, Bottiglieri T (2005) Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. Neurology 65:1402-1408.
17. Isobe C, Abe T, Terayama Y (2010) L-dopa therapy increase homocysteine concentration in cerebrospinal fluid from patients with Parkinson's disease. J Clin Neurosci 17:717-721.
18. Janssens V, Longin S, Goris J (2008) PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail). Trends Biochem Sci 33:113-121.
19. Jellinger KA (2011) Interaction between-Synuclein and Other Proteins in Neurodegenerative Disorders. ScientificWorldJournal 11:1893-1907.
20. Lee KW, Chen W, Junn E, Im JY, Grosso H, Sonsalla PK, Feng X, Ray N, Fernandez JR, Chao Y, Masliah E, Voronkov M, Braithwaite SP, Stock JB, Mouradian MM (2011) Enhanced phosphatase activity attenuatessynucleinopathy in a mouse model. J Neurosci 31:6963-6971.
21. Lei P, Ayton S, Finkelstein DI, Adlard PA, Masters CL, Bush AI (2010) Tau protein: relevance to Parkinson's disease. Int J Biochem Cell Biol 42:1775-1778.
22. Martin TM, Benghuzzi H, Tucci M (2005) The effect of conventional and sustained delivery of levodopa on SH-SY5Y neuroblastoma cells. BiomedSci Instrum 41:382-387.
23. Mattson MP, Shea TB (2003) Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 26:137-146.
24. McCully KS (2007) Homocysteine, vitamins, and vascular disease prevention. Am J Clin Nutr 86:1563S-1568S.
25. Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J, Joseph JA (1997) Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol 20:55-66.
26. Muller T, Kuhn W (2006) Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients. Eur J Clin Pharmacol 62:447-450.
27. Muller T, Kuhn W (2009) Homocysteine levels after acute levodopa intake in patients with Parkinson's disease. Mov Disord 24:1339-1343.
28. Nunbhakdi-Craig V, Schuechner S, Sontag JM, Montgomery L, Pallas DC, Juno C, Mudrak I, Ogris E, Sontag E (2007) Expression of protein phosphatase 2A mutants and silencing of the regulatory Balpha subunit induce a selective loss of acetylated and detyrosinated microtubules. J Neurochem 101:959-971.
29. Nutt JG (2001) Motor fluctuations and dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 8:101-108.
30. Ogburn KD, Bottiglieri T, Wang Z, Figueiredo-Pereira ME (2006) Prostaglandin J2 reduces catechol-O-methyltransferase activity and enhances dopamine toxicity in neuronal cells. Neurobiol Dis 22:294-301.
31. Ogris E, Gibson DM, Pallas DC (1997) Protein phosphatase 2A subunit assembly: the catalytic subunit carboxy terminus is important for binding cellular B subunit but not polyomavirus middle tumor antigen. Oncogene 15:911-917.
32. Poewe W, Antonini A, Zijlmans JC, Burkhard PR, Vingerhoets F (2010) Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin Interv Aging 5:229-238.
33. Rinne UK, Sonninen V, Sirtola T (1972) Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor. Z Neurol 202:1-20.
34. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN (1993) Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 43: 2685-2688.
35. Selhub J, Troen A, Rosenberg IH (2010) B vitamins and the aging brain. Nutr Rev 68 [Suppl 2]:S112-S118.
36. Sontag E, Nunbhakdi-Craig V, Bloom GS, Mumby MC (1995) A novel pool of protein phosphatase 2A is associated with microtubules and is regulated during the cell cycle. J Cell Biol 128:1131-1144.
37. Sontag E, Nunbhakdi-Craig V, Lee G, Bloom GS, Mumby MC (1996) Regulation of the phosphorylation state and microtubule-binding activity of Tau by protein phosphatase 2A. Neuron 17:1201-1207.
38. rd (2004) Downregulation of protein phosphatase 2A carboxyl methylation and methyltransferase may contribute to Alzheimer disease pathogenesis. J Neuropathol Exp Neurol 63:1080-1091.
39. Sontag E, Nunbhakdi-Craig V, Lee G, Brandt R, Kamibayashi C, Kuret J, White CL 3rd, Mumby MC, Bloom GS (1999) Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies. J Biol Chem 274:25490-25498.
40. Sontag E, Nunbhakdi-Craig V, Sontag JM, Diaz-Arrastia R, Ogris E, Dayal S, Lentz SR, Arning E, Bottiglieri T (2007) Protein phosphatase 2A methyltransferase links homocysteine metabolism with Tau and amyloid precursor protein regulation. J Neurosci 27:2751-2759.
41. Sontag JM, Nunbhakdi-Craig V, Montgomery L, Arning E, Bottiglieri T, Sontag E (2008) Folate deficiency induces in vitro and mouse brain region-specific downregulation of leucine carboxyl methyltransferase-1 and protein phosphatase 2A B(alpha) subunit expression that correlate with enhanced Tau phosphorylation. J Neurosci 28:11477-11487.
42. Stabler SP (2000) Using homocysteine and related metabolites to diagnose vitamin deficiency states. Biofactors 11:51-52.
43. Stacy M (2009) Medical treatment of Parkinson disease. Neurol Clin 27: 605-631, v.
44. Surtees R, Hyland K (1990) L-3,4-dihydroxyphenylalanine (levodopa) lowers central nervous system S-adenosylmethionine concentrations in humans. J Neurol Neurosurg Psychiatry 53:569-572.
45. Swoboda KJ (2006) Inherited disorders of amine biosynthesis. Future Neurol 1:605-614.
46. Ubbink JB, Hayward Vermaak WJ, Bissbort S (1991) Rapid highperformance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 565:441-446.
47. Wagner J, Danzin C, Huot-Olivier S, Claverie N, Palfreyman MG (1984) High-performance liquid chromatographic analysis of S-adenosylmethionine and its metabolites in rat tissues: interrelationship with changes in biogenic catechol levels following treatment with L-dopa. J Chromatogr 290:247-262.
48. Weingarten P, Bermak J, Zhou QY (2001 Mar) Evidence for non-oxidative dopamine cytotoxicity: potent activation of NF-kappa B and lack of protection by anti-oxidants. J Neurochem 76:1794-1804.
49. Xu Y, Chen Y, Zhang P, Jeffrey PD, Shi Y (2008) Structure of a protein phosphatase 2A holoenzyme: insights into B55-mediated Tau dephosphorylation. Mol Cell 31:873-885.
50. Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K (2000) Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 55:437-440.
51. Yoon SY, Choi HI, Choi JE, Sul CA, Choi JM, Kim DH (2007) Methotrexate decreases PP2A methylation and increases Tau phosphorylation in neuron. Biochem Biophys Res Commun 363:811-816.
52. Yuan RY, Sheu JJ, Yu JM, Hu CJ, Tseng IJ, Ho CS, Yeh CY, Hung YL, Chiang TR (2009) Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients. J Neurol Sci 287:64-68.
53. Zhou J, Austin RC (2009) Contributions of hyperhomocysteinemia to atherosclerosis: Causal relationship and potential mechanisms. Biofactors 35:120-129.
54. Zhuo JM, Wang H, Praticò D (2011) Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither? Trends Pharmacol Sci 32:562-571.
55. Zoccolella S, dell'Aquila C, Abruzzese G, Antonini A, Bonuccelli U, Canesi M, Cristina S, Marchese R, Pacchetti C, Zagaglia R, Logroscino G, Defazio G, Lamberti P, Livrea P (2009) Hyperhomocysteinemia in levodopatreated patients with Parkinson's disease dementia. Mov Disord 24:1028-1033.